[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Wall Street Bullish or Bearish on Johnson & Johnson Stock?

New Brunswick, New Jersey-based Johnson & Johnson (JNJ) engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. The company has a market cap of $616.5 billion and operates in two segments, Innovative Medicine and MedTech. 

Shares of Johnson & Johnson have outperformed the broader market over the past year, surging 54.1% compared to the S&P 500 Index’s ($SPX) 16.9% surge. Moreover, in 2026, the stock has risen by nearly 24.6%, also outpacing the SPX’s 8.7% gain.     

Fundamentals

See More
  • Market Capitalization, $K 616,500,096
  • Shares Outstanding, K 2,409,898
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,453 M
  • EBITDA $ 30,956 M
  • 60-Month Beta 0.24
  • Price/Sales 6.79
  • Price/Cash Flow 18.81
  • Price/Book 7.53

Options Overview Details

View History
  • Implied Volatility 24.80% (+0.37%)
  • Historical Volatility 30.17%
  • IV Percentile 78%
  • IV Rank 65.26%
  • IV High 30.74% on 07/07/26
  • IV Low 13.64% on 08/05/25
  • Expected Move (DTE 6) 5.56 (2.17%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 34,373
  • Volume Avg (30-Day) 37,224
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 397,632
  • Open Int (30-Day) 379,659
  • Expected Range 250.79 to 261.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $3.04
  • Number of Estimates 6
  • High Estimate $3.14
  • Low Estimate $2.94
  • Prior Year $2.80
  • Growth Rate Est. (year over year) +8.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
245.49 +4.42%
on 07/21/26
274.90 -6.75%
on 07/28/26
+2.38 (+0.94%)
since 06/30/26
3-Month
220.37 +16.33%
on 05/11/26
274.90 -6.75%
on 07/28/26
+26.50 (+11.53%)
since 04/30/26
52-Week
164.23 +56.09%
on 07/31/25
274.90 -6.75%
on 07/28/26
+89.09 (+53.26%)
since 07/30/25

Most Recent Stories

More News
Is Wall Street Bullish or Bearish on Johnson & Johnson Stock?

Johnson & Johnson has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.

XLV : 162.55 (-0.59%)
$SPX : 7,489.72 (+0.70%)
JNJ : 256.35 (+0.21%)
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Broadens capabilities in targeting pan-KRAS and other drivers of hard-to-treat cancers Adds novel degrader antibody conjugate platform designed to address...

JNJ : 256.35 (+0.21%)
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Advances differentiated immunology program with the potential to address significant unmet need in immune-mediated disease Novel in vivo CAR-T platform...

JNJ : 256.35 (+0.21%)
What Are Wall Street Analysts' Target Price for Kenvue Stock?

Kenvue has lagged the broader market over the past year, leaving analysts with a measured view on the stock.

$SPX : 7,489.72 (+0.70%)
JNJ : 256.35 (+0.21%)
KVUE : 19.24 (-0.36%)
XLP : 85.05 (-0.49%)
Wall Street's flip from AI to less-loved stocks accelerates, while oil prices keep easing

Most U.S. stocks rose after Coca-Cola and other companies reported stronger profits for the spring than analysts expected

NVDA : 200.75 (+2.93%)
META : 556.71 (+3.28%)
AMAT : 507.67 (+1.18%)
SHW : 340.85 (-1.16%)
KO : 87.59 (-1.02%)
$SPX : 7,489.72 (+0.70%)
JNJ : 256.35 (+0.21%)
MU : 823.03 (-5.90%)
$IUXX : 28,274.20 (+0.60%)
ITW : 286.95 (+1.15%)
MSFT : 464.72 (+3.02%)
SPCX : 108.37 (-3.41%)
Covista Names Emily C. Chiu and Leslie Storms to its Board of Directors

Appointments Deepen the Board’s Expertise Across Healthcare Delivery, Technology, Higher Education and Veterinary Medicine Supports Effective Oversight of the Company’s...

BNED : 12.44 (+0.16%)
JNJ : 256.35 (+0.21%)
XYZ : 81.24 (-1.63%)
CVSA : 124.85 (-1.26%)
Nasdaq Futures Plunge as Chip Selloff Rages On, FOMC Meeting and Earnings on Tap

September Nasdaq 100 E-Mini futures (NQU26) are down -1.07% this morning as investors continued to ditch chipmakers amid concerns over the sustainability of the AI spending boom.

KLAC : 182.82 (+1.38%)
FBRX : 76.60 (-0.49%)
PHIA.NA : 22.740 (-0.61%)
SNDK : 1,214.83 (-5.09%)
KO : 87.59 (-1.02%)
NQU26 : 28,404.25s (+0.59%)
ASML.NA : 1,434.200 (-0.40%)
JNJ : 256.35 (+0.21%)
MU : 823.03 (-5.90%)
AAL : 15.27 (-1.04%)
WDAY : 160.34 (+1.41%)
GLW : 138.25 (+2.24%)
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Follows Favorable Multi-District Litigation Court Causation Ruling and the Company’s Successful Strategy to Defend Each Case Efficient Conclusion to the Talc Litigation...

JNJ : 256.35 (+0.21%)
J&J Finally Has a Rival to da Vinci. 1 Number in Intuitive Surgical’s Last Quarter Says It Won’t Be Enough to Move the Needle for JNJ Stock.

J&J’s Ottava clearance knocked Intuitive's shares lower, but recurring revenue and surgeon switching costs suggest the market overreacted.

JNJ : 256.35 (+0.21%)
IHI : 52.51 (-0.44%)
MDT : 85.39 (-0.37%)
ISRG : 353.33 (+0.10%)
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

RARITAN, N.J. , July 23, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational...

JNJ : 256.35 (+0.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 263.98
2nd Resistance Point 261.23
1st Resistance Point 258.79
Last Price 256.35
1st Support Level 253.60
2nd Support Level 250.85
3rd Support Level 248.41

See More

52-Week High 274.90
Last Price 256.35
Fibonacci 61.8% 232.62
Fibonacci 50% 219.57
Fibonacci 38.2% 206.51
52-Week Low 164.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.